NUVB

Nuvation Bio Inc.

$1.97

0.18

(10.06%)

Exchange:	NYSE
Market Cap:	668.348M
Shares Outstanding:	80.992M

Overview

Earnings

Financials

Valuation

Chart

About The Company

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

EPS

View full analyst estimates

Earnings Call

No transcript or summary available for this symbol.

Income Statement

Balance Sheet

Cash Flow Statement

Analyst Estimates

Income Statement

(* All numbers are in thousands)

	2018	2019	2020	2021	2022	2023
? Revenue	0	0	0	0	0	0
? Cost Of Revenue	0	0	103	368	484	222
? Gross Profit	0	0	-103	-368	-484	-222
? Research And Development Expenses	482.667	25,106	32,603	69,037	87,815	71,289
? General And Administrative Expenses	509.333	6,593	10,948	24,281	31,919	26,833
? Selling And Marketing Expenses	0	400	0	0	0	-222
? Operating Expenses	992	32,180.999	43,551	93,318	119,734	99,600
? Net Interest Income	0	0	0	0	0	0
? Interest Income	0	1.371	1,945	2,963	7,448	24,611
? Interest Expense	0	0	0	0	-9,158	0
? Depreciation And Amortization	992	12.999	103	368	484	222
? EBITDA	0	-32,086	-43,666	-97,285	-128,693	-99,600
? EBIT
? Operating Income	-992	-32,098.999	-43,551	-93,318	-119,734	-99,822
? Income Before Tax	-992	-33,552	-41,659	-86,848	-104,199	-75,802
? Income Tax Expense	0	0	-2,163	-7,114	-15,535	0
? Net Income From Continuing Operations
? Net Income	-992	-33,552	-39,496	-79,734	-88,664	-75,802
? EPS (Earnings Per Share)	-0.010	-0.160	-0.400	-0.400	-0.410	-0.350
? EPS Diluted	-0.010	-0.160	-0.400	-0.400	-0.410	-0.350
? Weighted Average Shares Outstanding	80,992	206,672.251	97,530	197,887	216,721	218,880
? Weighted Average Shares Outstanding Diluted	80,989.011	206,672.024	97,530	197,887	216,721	218,880
	USD	USD	USD	USD	USD	USD

Balance Sheet

(* All numbers are in thousands)

	2018	2019	2020	2021	2022	2023
? Cash And Cash Equivalents	138	3,469	29,755	132,423	101,099	42,649
? Short Term Investments	0	115,401	185,997	632,969	559,915	568,564
? Cash And Short Term Investments	138	118,870	215,752	765,392	661,014	611,213
? Net Receivables	0	0	1,092	3,039	2,485	3,702
? Accounts Receivables
? Inventory	0	0	2,925	0	0	0
? Total Current Assets	158	119,885	220,683	772,073	667,318	616,434
? Property Plant Equipment Net	0	646	688	3,657	4,685	4,322
? Goodwill	0	0	0	0	0	0
? Intangible Assets	0	0	0	0	0	0
? Long Term Investments	0	0	0	0	-559,355.085	0
? Total Non Current Assets	0	1,067	1,109	4,078	4,823	5,050
? Total Assets	158	120,952	221,792	776,151	672,141	621,484
? Account Payables	83	2,029.999	2,171	3,925	2,139	2,209
? Short Term Debt	600	0	0	863	1,206	1,972
? Deferred Revenue	0	0	0	0	0	0
? Total Current Liabilities	902	3,204	6,551	16,925	13,161	13,974
? Long Term Debt	0	0	0	2,192	3,054	2,035
? Deferred Revenue Non Current	0	0	0	0	0	0
? Deferred Tax Liabilities Non Current	0	0	0	0	0	0
? Total Non Current Liabilities	0	0	157	13,229	3,904	2,387.999
? Total Liabilities	902	3,204	6,708	30,154	17,065	16,361.999
? Treasury Stock
? Preferred Stock	0	141,864	0	0	0	0
? Common Stock	0	9,759	289,482	909,985	927,604	947,745
? Retained Earnings	-744	-34,296	-75,955	-162,803	-267,002	-342,804
? Additional Paid In Capital
? Total Stockholders Equity	-744	117,748	215,084	745,997	655,076	605,122
? Total Equity	-744	117,748	215,084	745,997	655,076	605,122
? Minority Interest	0	0	0	0	0	0
? Total Liabilities And Total Equity	158	120,952	221,792	776,151	672,141	621,484
? Total Investments	0	115,401	185,997	632,969	559.915	568,564
? Total Debt	600	0	0	3,055	4,260	4,006.999
? Net Debt	462	-3,469	-29,755	-129,368	-96,839	-38,642.001
	USD	USD	USD	USD	USD	USD

Cash Flow Statement

(* All numbers are in thousands)

	2018	2019	2020	2021	2022	2023
? Net Income	-992	-33,552	-41,659	-86,848	-104,199	-75,802
? Depreciation And Amortization	0	13	103	184	199	222
? Deferred Income Tax	0	0	0	442	0	-21,104
? Stock Based Compensation	0	0	2,202	9,268	16,292	19,513
? Change In Working Capital	265.333	-460	2,110	4,793	-3,447	540
? Accounts Receivables	0	0	-264	-1,947	554	-1,217
? Inventory	0	0	264	1,947	-554	0
? Accounts Payables	0	0	34	1,861	-1,786	70
? Net Cash Provided By Operating Activities	-616	-24,432	-36,529	-68,190	-96,108	-67,999
? Investments In Property Plant And Equipment	0	-659	-145	-282	-370	-69
? Acquisitions Net	0	0	-2,508	454,669	13	14
? Purchases Of Investments	0	0	-143,289	-609,300	-520,307	-703,373
? Sales Maturities Of Investments	0	0	73,114	154,913	584,121	712,349
? Net Cash Provided By Investing Activities	0	0	0	0	0	0
? Net Debt Issuance	0	0	0	0	0	0
? Long Term Net Debt Issuance	0	0	0	0	0	0
? Short Term Net Debt Issuance	0	0	0	0	0	0
? Net Stock Issuance	0	0	0	0	0	0
? Net Dividends Paid	0	0	0	0	0	0
? Common Dividends Paid
? Preferred Dividends Paid	0	0	0	0	0	0
? Net Cash Provided By Financing Activities	800	143,618	133,135	625,527	1,327	628
? Effect Of Forex Changes On Cash	0	138	0	0	0	67,999
? Net Change In Cash	184	3,331.138	26,286	102,668	-31,324	-58,450
? Cash At End Of Period	184	3,469	29,755	132,423	101,099	42,649
? Cash At Beginning Of Period	0	137.862	3,469	29,755	132,423	101,099
? Operating Cash Flow	-616	-24,432	-36,529	-68,190	-96,108	-67,999
? Capital Expenditure	0	-659	-145	-282	-370	-69
? Free Cash Flow	-616	-25,091	-36,674	-68,472	-96,478	-68,068
	USD	USD	USD	USD	USD	USD

Analyst Estimates

(* All numbers are in thousands)

Fiscal Year	2024	2025	2026	2027	2028
Estimated Revenue (Low)	1,388.908	648.617	28,426.877	91,960.842	174,570.666
Estimated Revenue (High)	1,428.591	667.149	29,239.073	94,588.294	179,558.400
Estimated Revenue (Avg)	1,408.750	660.200	28,934.500	93,603	177,688
Estimated Ebitda (Low)	0	0	0	0	0
Estimated Ebitda (High)	0	0	0	0	0
Estimated Ebitda (Avg)	0	0	0	0	0
Estimated Net Income (Low)	-539,510.748	-175,104	-168,537.600	-118,703.002	-46,592.985
Estimated Net Income (High)	-69,463.757	-89,740.800	-122,572.800	-114,430.464	-44,916.365
Estimated Net Income (Avg)	-393,633.793	-150,410.750	-145,555.200	-117,100.800	-45,964.800
Estimated SGA Expense (Low)	0	0	0	0	0
Estimated SGA Expense (High)	0	0	0	0	0
Estimated SGA Expense (Avg)	0	0	0	0	0
Estimated EPS (Avg)	-1.800	-0.580	-0.670	-0.540	-0.210
Estimated EPS (High)	-0.320	-0.410	-0.560	-0.520	-0.210
Estimated EPS (Low)	-2.460	-0.800	-0.770	-0.540	-0.210
Number of Analysts (Estimated Revenue)	3	4	2	1	0
Number of Analysts (Estimated EPS)	4	4	2	0	1

Subscribe

Log in

Current Key Metrics

?	Revenue (TTM) :	0	?	P/S (TTM) :	61
?	Net Income (TTM) :	-75802000	?	P/E (TTM) :	-1.1
?	Enterprise Value (TTM) :	631.784M	?	EV/FCF (TTM) :	-5.5
?	Dividend Yield (TTM) :	0	?	Payout Ratio (TTM) :	0
?	ROE (TTM) :	-1.48	?	ROIC (TTM) :	-0.46
?	Net Debt (TTM) :	-537943000	?	Debt/Equity (TTM) :	0.03
?	P/B (TTM) :	1.59	?	Current Ratio (TTM) :	9.01